Ownership and insider activity for Adaptimmune Therapeutics plc (ADAP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
Price
| Price | $0.05 |
| Market Cap | $75M |
| Exchange | NASDAQ |
| Country | GB |
Balance Sheet (10y)
| Year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $229.1M | $158.8M | $84.0M | $68.4M | $50.4M | $56.9M | $149.9M | $108.0M | $144.0M | $91.1M |
| Short-term Investments | $55.3M | $22.7M | $124.2M | $136.8M | $39.1M | $311.3M | $219.6M | $96.6M | $2.9M | $60.5M |
| Receivables | $5.4M | $7.7M | $11.7M | $16.7M | $19.3M | $20.7M | $34.0M | $38.1M | $46.9M | $16.0M |
| Inventory | $102212 | $1.2M | $3.8M | $1.1M | $1.5M | 0 | 0 | 0 | 0 | $7.3M |
| Total Current Assets | $295.1M | $198.8M | $230.2M | $231.1M | $120.5M | $398.2M | $415.5M | $255.4M | $207.6M | $188.2M |
| Property, Plant & Equipment | $5.4M | $27.9M | $40.7M | $36.1M | $51.9M | $46.7M | $51.4M | $71.5M | $71.7M | $51.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $177692 | $1.3M | $1.3M | $1.5M | $2.2M | $1.7M | $1.0M | $442000 | $330000 | $3.9M |
| Total Assets | $300.7M | $234.5M | $281.1M | $276.7M | $181.5M | $451.1M | $469.5M | $328.9M | $282.6M | $246.0M |
| Accounts Payable | $7.8M | $11.3M | $8.4M | $4.1M | $6.4M | $6.4M | $8.1M | $4.8M | $8.1M | $8.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $26.8M | $40.3M | $74.3M | $24.4M | $34.3M | $39.1M | $62.5M | $64.5M | $72.8M | $64.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $50.2M |
| Total Liabilities | $41.1M | $68.4M | $78.2M | $29.9M | $57.9M | $109.9M | $263.6M | $247.0M | $243.1M | $234.1M |
| Retained Earnings | -$47.2M | -$161.5M | -$231.6M | -$318.5M | -$455.7M | -$585.8M | -$743.8M | -$909.3M | -$1.02B | -$1.09B |
| Total Equity | $259.6M | $166.1M | $203.0M | $246.9M | $123.6M | $341.2M | $206.0M | $81.9M | $39.5M | $11.8M |
| Total Debt | 0 | 0 | $124.2M | $136.8M | $25.5M | $23.7M | $25.5M | $23.1M | $25.2M | $74.2M |
| Net Debt | -$284.4M | -$181.5M | -$84.0M | -$68.4M | -$64.1M | -$344.5M | -$344.1M | -$181.5M | -$121.7M | -$77.4M |
| Working Capital | $268.3M | $158.5M | $155.9M | $206.7M | $86.1M | $359.1M | $352.9M | $190.9M | $134.8M | $123.6M |
Financial Health
| Debt / Equity | -0.69 |
| Current Ratio | 1.52 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -5.47 |
Profitability
| Return on Equity | 143.79% |
| Return on Invested Capital | -90.90% |
| Return on Assets | -59.65% |
| Gross Margin | 83.88% |
| Operating Margin | -362.66% |
| Net Margin | -371.74% |
Related companies: ANL · APLM · BLRX · ERNA · GOVX · LNAI · LPCN
Explore sector: Healthcare · Biotechnology
More sections of ADAP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks